CN100425251C - Pharmaceutical composition for treating bone diseases and method for preparing the same - Google Patents
Pharmaceutical composition for treating bone diseases and method for preparing the same Download PDFInfo
- Publication number
- CN100425251C CN100425251C CNB2005100023926A CN200510002392A CN100425251C CN 100425251 C CN100425251 C CN 100425251C CN B2005100023926 A CNB2005100023926 A CN B2005100023926A CN 200510002392 A CN200510002392 A CN 200510002392A CN 100425251 C CN100425251 C CN 100425251C
- Authority
- CN
- China
- Prior art keywords
- injection
- ethanol
- pharmaceutical composition
- treatment
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a pharmaceutical composition for treating bone diseases, especially injection of the pharmaceutical composition and a preparation method thereof. The pharmaceutical composition comprises extracting liquid of bones of pig limbs and extracting liquid of muskmelon seeds. The preparation method of the injection has the steps that (1) cleaned bones of pig limbs are extracted to obtain extracting liquid of bones of pig limbs; (2) dry and ripe seeds of a muskmelon are extracted to obtain the extracting liquid of muskmelon seeds; (3) the two kinds of extracting liquid are mixed to be prepared into the injection by a conventional method in the same field. The pharmaceutical composition has favorable therapeutic effects on common bone diseases, such as hyperplastic osteoarthropathy, rheumatism, rheumatoid arthritis, osteoarthritis, waist and leg pains, etc., and can accelerate the immediate union of fracture, the recovery of wound, etc.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of osteopathia and preparation method thereof, especially a kind of ejection preparation and preparation method thereof.
Background technology
Common clinically osteopathia, as various arthritis such as rheumatic arthritis, rheumatoid arthritis and degenerative osteoarthritis, ankylosing spondylitis, cervical spondylosis, prolapse of lumbar intervertebral disc and osteoporosis etc., it is puzzlement patient's common property disease, osteopathia is not easy treatment, and recurrence easily, give patient physiological and cause very big burden psychologically.
The arthralgia that causes for rheumatic arthritis and rheumatoid arthritis generally adopts analgesic, nonsteroidal antiinflammatory drug or hormone medicine treatment clinically.These medicines can really play and improve the state of an illness, the effect of control disease development, but significant side effects is arranged, the untoward reaction incident happens occasionally, and patient tolerability is poor, and the state of an illness easily recurs after the drug withdrawal.
In " national essential drugs preparation variety catalogue ", in antipyretic analgesic, antiinflammatory, the rheumatism chemical drugs classification, the injection dosage form is few, wherein have only two kinds of injection dosage forms of acetaminophen and ibuprofen, but the life-time service acetaminophen all has infringement to liver, kidney, especially renal colic or acute renal failure (oliguria, uremia) may appear in poor kidney person.Also methemoglobinemia can take place in addition, clinical manifestation mainly is pain relieving, and the antiinflammatory rheumatism almost is of no curative effect.Ibuprofen finds that in untoward reaction is investigated the intestines and stomach is had zest, generally shows as gastrointestinal upset, erythra, headache, tinnitus, and can make previously has the human bronchial spasm of allergies to increase the weight of, and the incidence rate of various erythra or other dermoreactions is higher.And other medicines are single chemosynthesis medicine and single Chinese medicine extract mostly, mostly are solid preparation on dosage form, and taking for a long time has zest to gastrointestinal.
Summary of the invention
The object of the present invention is to provide pharmaceutical composition of a kind of pharmaceutical composition for the treatment of osteopathia, especially treatment of arthritis and preparation method thereof.The preferred ejection preparation of this medicine does not have zest to patient's gastrointestinal, and does not have other side effect.
The objective of the invention is to be achieved through the following technical solutions.
The pharmaceutical composition of the treatment osteopathia that the present invention proposes comprises following composition: pig limbs bone extracting solution and Fructus Melo seed (Cucumis melo L.) extracting solution.
Preferably include:, 10-30 weight portion Fructus Melo seed is extracted the extracting solution of gained the extracting solution of 40-60 weight portion pig limbs bone extraction gained.
More preferably comprise: with the extracting solution of 50 weight portion pig limbs bones, the extracting solution of 20 weight portion Fructus Melo seeds.
The present invention also provides the preparation method of aforementioned pharmaceutical compositions injection, and this method may further comprise the steps:
(1) the pig limbs bone water decoction of cleaning is extracted, obtain the pig limbs bone extracting solution;
(2) the seed water of the drying and ripening of Fructus Melo is decocted extract, preferably will use water boiling and extraction after the seed fragmentation, obtain Fructus Melo seed extracting solution;
(3) two kinds of extracting solution are mixed by above-mentioned weight proportion, make injection with the conventional method of this area.
Wherein, the pig limbs bone extracting solution of step (1) gained can also be handled through peracid, alkali or alcohol, makes extracting solution purer;
The Fructus Melo seed extracting solution of step (2) gained can also make this extracting solution purer through alcohol or washing.
The method for preparing this medicine composition injection preferably includes:
(1) pig limbs bone with cleaning extracts for its decocting of 2 times boils with weight respectively, extract 2 times, each 1 hour, merge gained pig limbs bone extracting solution, then extracting liquid volume is concentrated into 1/3, handles with hydrochloric acid, sodium hydroxide solution and ethanol precipitation successively, reclaim ethanol, filter filtrate for later use then;
(2) after the seed fragmentation with the drying and ripening of Fructus Melo, extract for 6,4 times decocting 8, boils with weight successively, each 50 minutes, merge extractive liquid,, extracting liquid volume is concentrated into 1/3, filter, filtrate is washed and reclaim ethanol with ethanol, washing, ethanol is washed and reclaimed to ethanol once more, filtrate for later use is filtered in washing;
(3) two kinds of filtrates are mixed, heat little cooling then of boiling, filter, ultrafiltration adds water for injection, adds active carbon, filters, and transferring the pH of solution is between 6.5～7.0, and sampling detects content of peptides, and check is canned, sterilization, lamp inspection, packing.
The pharmacological action of pharmaceutical composition proposed by the invention is as follows:
Contain the bone polypeptide class bone metabolism factor in the pig limbs bone extracting solution, can effectively promote influence in the body the synthesizing of bdgf of bone formation and absorption, comprise bone morphogenetic protein (BMPs), β-transforming growth factor (TGF-β) and fibroblast growth factor (FGF) etc., thereby have multiple biological activity, can promote mitosis, differentiation, chemotaxis and the molten bone active etc. of cell.Wherein BMPs is one group of acid low-molecular-weight glycoprotein, as a kind of efficient bone Induced substance, BMPs is that mesenchymal cell is the initially signal molecule of cell differentiation to bone, the bone that the mesenchymal cell that moves about around the energy induction of vascular is converted into irreversibility is a cell, be chondrocyte and osteoblast, thereby the promotion callus formation arrives new bone formation again, promotes fracture repair; In addition, BMPs is the change of scalable extracellular matrix components also, and by inducing new bone formation better with TGF-β and FGF coordinative role each other, makes osseous tissue more ripe.TGF-β then is one group of protein polypeptide with multiple function, with the multiple factor such as extracellular matrix and the collaborative adjusting that participates in the pair cell differentiation of other differentiation adjusting somatomedin; TGF-β can promote extracellular matrix synthetic, can directly lunge the synthetic of fibroblast epimatrix, and its new synthetic substrate degradation is had remarkable inhibitory action; For osteoblast, TGF-β can promote its synthetic type i collagen, bone conglutination element and osteopontin; Simultaneously, TGF-β shows that to the effect of lymphocyte and macrophage it can alleviate the destructiveness of inflammatory reaction, can assist some macrophage derived cytokine to play a role in tissue repair again.FGF is one group of bonding polypeptide of heparin, but the trend of irritation cell move, breed and break up, increase the quantity of rubber polymer archeocyte, promote the synthetic of bone collagen and noncollagen protein, increase the synthetic of Bone Gla protein.
Fructus Melo seed extracting solution can reduce the local capillary permeability of fracture, reduces inflammatory exudation, promotes the recovery of local blood fortune obstacle; Simultaneously can also reduce whole blood viscosity and cell aggregation degree, improve the partial blood circulation of callus, for osteocyte provides a good blood supply environment; Can also suppress the release of prostaglandin in addition, reach analgesic effect; In promoting fracture heals in early days, Fructus Melo seed extracting solution and polypeptides bone metabolic factor have synergism, promote the synthetic of bdgf.
Also contain multiple free amino acid in the pharmaceutical composition of the present invention, supply raw materials, promote the synthetic of bdgf for bdgfs such as osteocyte synthetic BMPs, TGF-β and FGF.The organic calcium phosphonium ion can participate in this phosphorus metabolism, keeps bone volume.
Using method: contain with the injection of every milliliter of medicine of the present invention and to be not less than 5.0mg.The polypeptide amount is calculated, intramuscular injection every day 2 times, each 2-5 milliliter; Intravenous injection every day 1 time, each 10-20 milliliter joins in 250 ml physiological salines or the glucose injection and uses; 20-30 day is a course of treatment.
Pharmaceutical composition of the present invention can be used for the treatment of common osteopathia is had excellent curative, as the hypertrophy joint disease, and rheumatism, rheumatoid arthritis, osteoarthritis, lumbago and skelalgia, and can promote the immediate union, wound recovery etc. of fracture; Proved the curative effect of this pharmaceutical composition by clinical trial.
Medicine of the present invention has no adverse reaction, and blood and biochemical indicator no abnormality seen have no side effect in acute and slow acute experiment.Anaphylaxis and toxicity are not also found in patient's blood, urine, just routine examination and all no abnormal variation of hepatic and renal function inspection in the clinical trial before and after clinical observation treatment, this product determined curative effect are described, avirulence, clinical drug safety.Medicine of the present invention is a compound preparation, can reach good effect at this medicine of the single use of treatment clinical course, has no adverse reaction, and few side effects does not need the other drug auxiliary treatment, has reduced drug combination.
Below further specify the good result of this medicine by the clinical trial of medicine of the present invention.
From the clinical practice situation, this medicine injection is obvious to the therapeutic effect of rheumatoid arthritis and degenerative osteoarthritis etc., and total effective rate reaches 92.9% and 94.87%.
1. the clinical research of medicaments injection associating ibuprofen treatment rheumatoid arthritis of the present invention and degenerative osteoarthritis: adopt randomized controlled trial, select for use ibuprofen as basic medication.Test group is totally 94 examples, rheumatoid arthritis 55 examples wherein, degenerative osteoarthritis 39 examples.Matched group is totally 58 examples, rheumatoid arthritis 37 examples wherein, degenerative osteoarthritis 21 examples.Test group and matched group all are complementary from age, sex, the course of disease, function of joint classification etc., have increased the comparability of data.
Result of the test shows: test group and treatment of control group rheumatoid arthritis and degenerative osteoarthritis are all effective, but the curative effect that adds with medicaments injection of the present invention obviously is better than ibuprofen, treatment rheumatoid arthritis total effective rate is respectively 92.9% and 86.49%, and the degenerative osteoarthritis total effective rate is respectively 94.87% and 76.19%.The adverse reaction rate of test group and matched group is respectively 10.85% and 19.66%.Especially at aspects such as articular pain number, arthroncus number, grip increase, 15m walking time shortening, erythrocyte sedimentation rate and the improvement of c reactive protein effective percentage obvious curative effects is arranged all.More be better than ibuprofen with medicaments injection of the present invention and use (P＜0.01) separately and add aspect the increase by two of articular pain number, grip in the comparison that every index is improved between two groups, this and medicaments injection of the present invention improve blood viscosity, alleviate the joint oozes out, analgesic activity is directly relevant, arthralgia is alleviated, and function of joint also can make moderate progress.
2. medicaments injection treatment rheumatoid arthritis of the present invention and ankylosing spondylitis 50 routine clinical observations: rheumatoid arthritis and ankylosing spondylitis all belong to commonly encountered diseases, frequently-occurring disease.This sick touching difficulty heals, and severe patient causes lifelong deformity, the serious harm people health.Test is in the morning before and after the patient treatment stiff time, allomeric function, and pain, tenderness, swelling and the joint movement disorder etc. of local joint symptom that the laboratory is checked and reflection is got involved change as parameters for observation on effect.Result of the test shows that medicaments injection of the present invention has following advantage: 1. produce effects is fast, and most of patients can show therapeutic effect at the back 7～10d that takes medicine; 2. effective percentage height, this group case shows that this medicine effective percentage is 88%, clinic control and obvious effective rate are 48%, are better than Western medicine two, three-way antirheumatic and some Chinese patent medicine; 3. untoward reaction is few, and this organizes 50 routine patients, and the short time innerlich anwenden has no adverse reaction; 4. scope of medication is extensive, because medicaments injection of the present invention has effects such as antiinflammatory, analgesia and immunosuppressant and adjusting simultaneously, this medicine can be widely used in rheumatoid arthritis and early, middle and late each the phase patient of ankylosing spondylitis, and certain etiological treatment effect is arranged.
3. the clinical research of medicaments injection of the present invention and Glucosidorum Tripterygll Totorum treatment active stage rheumatic arthritis: rheumatic arthritis is a kind of autoimmune disease based on the joint symptom, have repeatedly outbreak, characteristics that disability rate is high, belong to common and refractory disease.
This test is by 153 examples (be divided into medicaments injection treatment group 92 examples of the present invention and Radix Tripterygii Wilfordii treatment at random and organize 61 examples) active stage rheumatic arthritis patient clinical observation, the result shows: medicaments injection treatment group clinical cure obvious effective rate of the present invention is 80.4%, total effective rate 91.3%, cardinal symptom and sign all have significance to improve; The infrared heat image detection shows that patient's both hands articulations digitorum manus surface temperature significantly descends; Inflammatory Mediators detects and shows that erythrocyte sedimentation rate, c reactive protein all have significance to descend; Hemorheology detects and shows that every index all has significance to reduce.Each curative effect index of medicaments injection of the present invention all obviously is better than Radix Tripterygii Wilfordii group (the clinical cure obvious effective rate is 68.5%, and total effective rate is 76.2%).Conclusion: the bone-melon extract injection has significant therapeutical effect to the rheumatic arthritis active stage.Result of the test discloses: medicaments injection of the present invention can improve patient's the every detection index of symptom, sign and ESR, CRP, infrared heat image, hemorheology effectively, anti-inflammatory analgesic, suppress the synovial membrane inflammatory lesion, the purpose that reaches the disease controlling activity, alleviates clinical symptoms, improves function of joint, improves the quality of living is the comparatively ideal medicine of treatment active stage RA.
4. medicaments injection of the present invention treatment rheumatoid arthritis: in recent years, international rheumatism alliance is divided into the rheumatism treatment (SMARDS) that improves symptom and rheumatism treatment (DCART) two big classes of disease controlling to the treatment region of RA.DCART is meant that certain Therapeutic Method energy useful effect in synovium of joint, stops the sclerotin invasion and attack, improves function of joint.So far do not find as yet that a kind of medicine really belongs to DCART, because present medicine finally fails effectively to stop the sclerotin invasion and attack.Stoping the sclerotin invasion and attack is treatment emphasis of RA.
After using medicaments injection treatment of the present invention, by the contrast of the X-ray film sign before and after the treatment, osteoporosis improvement rate 69.6%, bone erosion improvement rate 45.5%, arthrostenosis improvement rate 18.9%.Demonstrate this medicine and aspect the invasion and attack of prevention sclerotin sure effect is being arranged.
5. medicaments injection treatment vertebral artery type of cervical spondylosis of the present invention: medicaments injection of the present invention is assisted cervical vertebrae traction vertebral artery type of cervical spondylosis 53 examples, male 23 examples, women 30 examples, 28 years old～56 years old age, 42 years old mean age.The course of disease 3 months is with interior 42 examples, 3 months～1 year 2 months 11 examples, complicated hypertension, atherosclerosis 8 examples.Revolve positive 49 examples of neck provocative test, dizzy companion's one side 41 examples of having a headache, tinnitus companion visual deterioration 12 examples are felt sick, vomiting companion upper limb muscular hypotonus 5 examples, because of violent dizzy 2 examples of dampinging off.Hear vertebral artery blood flow noise 6 examples of being obstructed on the Ipsilateral clavicle.Radiographic test: C
2～C
7(the 2nd to the 7th neck bone) all has the different cervical flexure of degree to become straight, narrowing of intervertebral space, vertebral body trailing edge hyperosteogeny, and zygapophysial joints rotation displacement, uncovertebral joint hypertrophy, transverse foramen sagittal diameter and transverse diameter narrow down.This group 53 example recoveries from illness 34 examples, produce effects 12 examples, progressive 6 examples, invalid 1 example.Total effective rate 98.2%.The curative effect of medicaments injection of the present invention is not only oozed out with the osteoarticular hyperosteogeny of its improvement, minimizing inflammation, the soft tissue edema is relevant, and wherein the Fructus Melo seed extract improves blood circulation, reduce blood viscosity, dizzy, tinnitus that vertebral artery compressing ischemia is caused have good improvement.
6. medicaments injection treatment prolapse of lumbar intervertebral disc of the present invention: 80 routine prolapse of lumbar intervertebral disc patients, male 58 examples, women 22 examples; 19～65 years old age; The course of disease 7 days～10 years.CT result: prolapse of lumbar intervertebral disc 71 examples, bulging 9 examples; Dural sac, root compression 70 examples; L
4,5(fourth lumbar vertebra is to fifth lumbar vertebra) gives prominence to 56 examples, L
5S
1(fifth lumbar vertebra is to first sacral vertebra) gives prominence to 22 examples, L
3.4Outstanding 2 examples (third lumbar vertebra is to fourth lumbar vertebra); Wherein two intervertebral disc are all seen outstanding 17 examples, and three intervertebral disk hernia are or/and bulging 10 examples.History of operation 5 examples are previously arranged.Treatment back is by 45 examples of fully recovering of the criterion of therapeutical effect in the prolapse of lumbar intervertebral disc new drug guideline, produce effects 24 examples, effective 8 examples, invalid 2 examples.
7. medicaments injection treatment postmenopausal women osteoporosis of the present invention: select more than 45 years old, the sufferers of osteoporosis face in 1～10 year of menopause, 14 examples, the bone density of its lumbar vertebra or hipbone are lower than preceding two standard deviations of women's bone density meansigma methods of normal menopause.All patients respectively carry out hepatic and renal function 1 time before medication and after 6 weeks of medication, blood calcium, phosphorus, alkali phosphatase, and erythrocyte sedimentation rate, routine blood test, urine calcium, phosphorus, Ca/Cr check.Adopt dual energy X-ray absorptiometry to measure the bone density of lumbar vertebra and right hipbone.Effectively: bone density remains unchanged or rises; Invalid: patient's bone density continues to descend.The result shows: effective 12 examples among the 14 routine patients.Except that 1 routine 2 weeks of patient's private prosecution medication occurred not having other discomforts the flush.Conclusion: medicaments injection of the present invention is a kind of medicine that is used for the treatment of postmenopausal osteoporosis preferably, can effectively keep, bone density improving better tolerance, few side effects.
The specific embodiment
Embodiment 1
The clean pig limbs bone of 50kg was respectively extracted 1 hour with 100 liters of pure water respectively, extract altogether twice, merge extractive liquid,, extracting liquid volume is concentrated into 1/3, regulates pH value to 3.5 ± 0.2,10% sodium hydroxide solution with dilute hydrochloric acid solution successively and adjust PH to 9.0 ± 0.2,80% washing with alcohol and precipitation, reclaim ethanol, filter filtrate for later use then.
The exsiccant Fructus Melo seed of 20kg is cleaned, and fragmentation is extracted 3 times with 160,120,80 liters of pure water successively, each 50 minutes, merge extractive liquid, is concentrated into 1/3 with extracting liquid volume, filters, filtrate is washed and reclaims ethanol with ethanol, washing, ethanol is washed and reclaimed to ethanol once more, washing, filter filtrate for later use.
Two kinds of filtrates are mixed, heat little cooling then of boiling, filter, ultrafiltration adds water for injection 22500mL, adds 0.2% active carbon 45g, filter, transferring the pH of solution is between 6.5～7.0, and sampling detects content of peptides, carry out rare stirring of joining by 6mg/ml, carry out the inspection of semifinished product, canned, sterilization, lamp inspection, packing.
Specification: every injection volume is 5mL, contains polypeptide 30mg/ and props up.
Embodiment 2
Get clean pig limbs bone of 60kg and the exsiccant Fructus Melo seed of 30kg, prepare injection by the method for embodiment 1.Wherein, acid is dilute hydrochloric acid, regulates pH value to 3.5 ± 0.2; Alkali is 10% sodium hydroxide, adjusts PH to 9.0 ± 0.2; With 75% ethanol washing with alcohol and precipitation, reclaim ethanol, filter filtrate for later use then; Add water for injection 29100mL, add 0.2% active carbon 58g, filter, transfer the pH of solution to add as between 6.5～7.0, sampling detects content of peptides, carries out rare stirring of joining by 6mg/ml, carries out the inspection of semifinished product, fill, sterilization, lamp inspection, packing.Every injection volume is 2mL, contains polypeptide 12mg/ and props up.
Embodiment 3
Get clean pig limbs bone of 40kg and the exsiccant Fructus Melo seed of 10kg, prepare injection by the method for embodiment 1.Wherein, acid is dilute hydrochloric acid, regulates pH value to 3.5 ± 0.2; Alkali is 10% sodium hydroxide, adjusts PH to 9.0 ± 0.2; With 85% washing with alcohol and precipitation, reclaim ethanol, filter filtrate for later use then; The concentration of alcohol of washing Fructus Melo seed extracting solution is respectively [(contain the alcohol amount and reach 70%) and (contain the alcohol amount and reach 80%)]; Add water for injection 16200mL, add 0.2% active carbon 32g, filter, the pH that transfers solution be what between 6.5～7.0, sampling detects content of peptides, carries out rare stirring of joining by 6mg/ml, carries out the inspection of semifinished product, fill, sterilization, lamp inspection is packed.Every injection volume is 5mL, contains polypeptide 30mg/ and props up.
Claims (2)
1, a kind of preparation is used for the treatment of the method for osteopathia medicine composition injection, and this method comprises:
(1) pig limbs bone with cleaning extracts for its decocting of 2 times boils with weight respectively, extract 2 times, each 1 hour, merge gained pig limbs bone extracting solution, then extracting liquid volume is concentrated into 1/3, handles with hydrochloric acid, sodium hydroxide solution and ethanol precipitation successively, reclaim ethanol, filter filtrate for later use then;
(2) after the seed fragmentation with the drying and ripening of Fructus Melo, extract for 6,4 times decocting 8, boils with weight successively, each 50 minutes, merge extractive liquid,, extracting liquid volume is concentrated into 1/3, filter, filtrate is washed and reclaim ethanol with ethanol, washing, ethanol is washed and reclaimed to ethanol once more, filtrate for later use is filtered in washing;
(3) two kinds of filtrates are mixed, heat little cooling then of boiling, filter, ultrafiltration adds water for injection, adds active carbon, filters, and transferring the pH of solution is between 6.5～7.0, and sampling detects content of peptides, and check is canned, sterilization, lamp inspection, packing.
2, method as claimed in claim 1 in (1), is 3.5 ± 0.2 with salt acid treatment to pH value of solution wherein, with sodium hydroxide solution handle to pH value of solution be 9.0 ± 0.2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100023926A CN100425251C (en) | 2005-01-19 | 2005-01-19 | Pharmaceutical composition for treating bone diseases and method for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100023926A CN100425251C (en) | 2005-01-19 | 2005-01-19 | Pharmaceutical composition for treating bone diseases and method for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1806816A CN1806816A (en) | 2006-07-26 |
| CN100425251C true CN100425251C (en) | 2008-10-15 |
Family
ID=36839026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100023926A Active CN100425251C (en) | 2005-01-19 | 2005-01-19 | Pharmaceutical composition for treating bone diseases and method for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100425251C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101866321B (en) * | 2010-06-13 | 2012-03-21 | 北京北大众志微系统科技有限责任公司 | Adjustment method and system for cache management strategy |
| CN103070906A (en) * | 2011-12-08 | 2013-05-01 | 赵联华 | Quality control method of injection composition for treating orthopedic diseases |
| CN103040911A (en) * | 2011-12-08 | 2013-04-17 | 赵联华 | Composition for injection for treating orthopedic diseases |
| CN102441023B (en) * | 2011-12-08 | 2013-05-01 | 赵联华 | Injection composition for treating orthopedic diseases |
| CN104127473B (en) * | 2014-07-31 | 2017-12-29 | 哈尔滨圣泰生物制药有限公司 | A kind of pharmaceutical composition for treating bone disease and its injection and preparation method |
| CN107595924B (en) * | 2017-09-21 | 2021-02-09 | 哈尔滨松鹤制药有限公司 | Preparation method of bone-melon extract injection and corresponding pharmaceutical composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356130A (en) * | 2001-10-30 | 2002-07-03 | 崔青云 | Medicine for treating bone fracture |
| CN1470256A (en) * | 2002-07-26 | 2004-01-28 | 哈尔滨誉衡药业有限公司 | Medicinal composition for promoting bone-fracture healing and bone-joint injure repairing |
-
2005
- 2005-01-19 CN CNB2005100023926A patent/CN100425251C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356130A (en) * | 2001-10-30 | 2002-07-03 | 崔青云 | Medicine for treating bone fracture |
| CN1470256A (en) * | 2002-07-26 | 2004-01-28 | 哈尔滨誉衡药业有限公司 | Medicinal composition for promoting bone-fracture healing and bone-joint injure repairing |
Non-Patent Citations (2)
| Title |
|---|
| 国家药品西药标准. 国家药典委员肝，203，国家药品监督管理局. 2003 |
| 国家药品西药标准. 国家药典委员肝，203，国家药品监督管理局. 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1806816A (en) | 2006-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100425251C (en) | Pharmaceutical composition for treating bone diseases and method for preparing the same | |
| CN104042893A (en) | Traditional Chinese medicine preparation for treating gout and preparation method of traditional Chinese medicine preparation | |
| CN103463624A (en) | Bone joint composite nutrient supplement and preparation method thereof | |
| CN1628768A (en) | Medicine for treating gout affection and its symptoms | |
| CN102441023B (en) | Injection composition for treating orthopedic diseases | |
| CN1207022C (en) | Medicinal composition for promoting bone-fracture healing and bone-joint injure repairing | |
| CN1310664C (en) | Chinese medicine capsule for treating cardiac and cerebral vascular diseases and its production process | |
| CN102793870B (en) | Chinese herbal medicine for treating renal calculi | |
| CN105168284A (en) | Application of panax japonicus saponins V and total panax japonicus saponins thereof to preparation of medicament for resisting urathritis | |
| CN101716248B (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN107468768A (en) | A kind of Qiang's drug composition and application thereof | |
| CN102552715B (en) | Chinese medicinal composition, medicine containing Chinese medicinal composition and preparation method of medicine | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN112121082A (en) | Chinese herbal medicine for treating rheumatoid arthritis and ankylosing spondylitis osteoarthropathy | |
| CN1255155C (en) | Medicine for curing rheumatic and rheumatoid diseases and its preparing method | |
| CN1742963A (en) | Chinese medicine for treating diabets and nephritis | |
| CN102302619B (en) | Medicine for treating gout | |
| CN105617161A (en) | Traditional Chinese medicine composition for treating gout | |
| CN102940671B (en) | Medicine composition for treating diabetic foot | |
| CN104758503B (en) | It is a kind of promote union composition and its decocting liquid preparation method | |
| CN100528197C (en) | Chinese medicinal electuary for treating ankylosing spondylitis | |
| CN1931187A (en) | Application of high purity and high adsorption nanometer microporous charcoal powder in preparing medicine for treating uric acid disease | |
| CN1539448A (en) | Drug for curing reheumatoid arthritis and atrophic artjritis | |
| CN106309566A (en) | Medicine for treating cardiovascular and cerebtovascular diseases and osteoarthrosis and preparation method of capsule | |
| AU2016102079A4 (en) | Chinese herbal medicine for treating gout and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: HARBIN SANCTITY BIOLOGICAL PHARMACEUTICAL CO., LTD. Assignor: Shengtai Pharmaceutical Co., Ltd., Harbin Contract record no.: 2011230000301 Denomination of invention: Pharmaceutical composition for treating bone diseases and method for preparing the same Granted publication date: 20081015 License type: Exclusive License Open date: 20060726 Record date: 20111027 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: HARBIN SANCTITY BIOLOGICAL PHARMACEUTICAL CO., LTD. Assignor: Shengtai Pharmaceutical Co., Ltd., Harbin Contract record no.: 2011230000301 Date of cancellation: 20120330 |
|
| ASS | Succession or assignment of patent right |
Owner name: HARBIN SANCTITY BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHENGTAI PHARMACEUTICAL CO., LTD., HARBIN Effective date: 20120507 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120507 Address after: 150025 No. 99 Beijing Road, Limin Development Zone, Heilongjiang, Harbin Patentee after: HARBIN SANCTITY BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: 150025, 99 Beijing Road, Limin economic and Technological Development Zone, Heilongjiang, Harbin Patentee before: Shengtai Pharmaceutical Co., Ltd., Harbin |